{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,20]],"date-time":"2026-09-20T21:34:57Z","timestamp":1789940097681,"version":"4.0.1"},"reference-count":34,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2014,6,11]],"date-time":"2014-06-11T00:00:00Z","timestamp":1402444800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2014,6,11]],"date-time":"2014-06-11T00:00:00Z","timestamp":1402444800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["AAPS J"],"DOI":"10.1208\/s12248-014-9623-6","type":"journal-article","created":{"date-parts":[[2014,6,10]],"date-time":"2014-06-10T17:47:00Z","timestamp":1402422420000},"page":"1009-1017","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":19,"title":["Population Pharmacokinetic Modeling of LY2189102 after Multiple Intravenous and Subcutaneous Administrations"],"prefix":"10.1208","volume":"16","author":[{"given":"S\u00e9bastien","family":"Bihorel","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jill","family":"Fiedler-Kelly","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elizabeth","family":"Ludwig","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joanne","family":"Sloan-Lancaster","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eyas","family":"Raddad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2014,6,11]]},"reference":[{"key":"9623_CR1","doi-asserted-by":"publisher","first-page":"519","DOI":"10.1146\/annurev.immunol.021908.132612","volume":"27","author":"CA Dinarello","year":"2009","unstructured":"Dinarello CA. Immunological and inflammatory functions of the interleukin-1 family. Annu Rev Immunol. 2009;27:519\u201350.","journal-title":"Annu Rev Immunol"},{"key":"9623_CR2","unstructured":"Kineret (anakinra) [package insert]. Stockholm, Sweden: Swedish Orphan Biovitrum AB; 2012. http:\/\/www.kineretrx.com\/fileadmin\/user_upload\/kineretus\/documents\/Kineret_Full_Prescribing_Information.pdf. Published Dec 2012. Accessed 20 Feb 2014."},{"key":"9623_CR3","unstructured":"Kineret (anakinra). Summary of product characteristics. 2002. http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/EPAR_-_Product_Information\/human\/000363\/WC500042310.pdf. Accessed 20 Feb 2014."},{"issue":"Suppl 1","key":"9623_CR4","first-page":"S7","volume":"51","author":"MY Donath","year":"2008","unstructured":"Donath MY, Weder C, Whitmore J, Bauer RJ, Der K, Scannon PJ, et al. XOMA 052, an anti\u2013IL\u20131\u03b2 antibody, in a double-blind, placebo-controlled, dose escalation study of the safety and pharmacokinetics in patients with type 2 diabetes mellitus\u2014a new approach to therapy. Diabetologia. 2008;51 Suppl 1:S7.","journal-title":"Diabetologia"},{"issue":"15","key":"9623_CR5","doi-asserted-by":"publisher","first-page":"1517","DOI":"10.1056\/NEJMoa065213","volume":"356","author":"CM Larsen","year":"2007","unstructured":"Larsen CM, Faulenbach M, Vaag A, V\u00f8lund A, Ehses JA, Seifert B, et al. Interleukin\u20131\u2013receptor antagonist in type 2 diabetes mellitus. N Engl J Med. 2007;356(15):1517\u201326.","journal-title":"N Engl J Med"},{"issue":"9","key":"9623_CR6","doi-asserted-by":"publisher","first-page":"1663","DOI":"10.2337\/dc09-0533","volume":"32","author":"CM Larsen","year":"2009","unstructured":"Larsen CM, Faulenbach M, Vaag A, Ehses JA, Donath MY, Mandrup-Poulsen T. Sustained effects of interleukin-1 receptor antagonist treatment in type 2 diabetes. Diabetes Care. 2009;32(9):1663\u20138. doi:10.2337\/dc09-0533.","journal-title":"Diabetes Care"},{"issue":"6","key":"9623_CR7","doi-asserted-by":"publisher","first-page":"851","DOI":"10.1172\/JCI200215318","volume":"110","author":"K Maedler","year":"2002","unstructured":"Maedler K, Sergeev P, Ris F, Oberholzer J, Joller-Jemelka HI, Spinas GA, et al. Glucose\u2013induced beta cell production of IL\u20131beta contributes to glucotoxicity in human pancreatic islets. J Clin Invest. 2002;110(6):851\u201360.","journal-title":"J Clin Invest"},{"issue":"8","key":"9623_CR8","doi-asserted-by":"publisher","first-page":"1683","DOI":"10.2337\/diabetes.50.8.1683","volume":"50","author":"K Maedler","year":"2001","unstructured":"Maedler K, Spinas GA, Lehmann R, Sergeev P, Weber M, Fontana A, et al. Glucose induces beta\u2013cell apoptosis via upregulation of the Fas receptor in human islets. Diabetes. 2001;50(8):1683\u201390.","journal-title":"Diabetes"},{"issue":"7","key":"9623_CR9","doi-asserted-by":"publisher","first-page":"1706","DOI":"10.2337\/diabetes.53.7.1706","volume":"53","author":"K Maedler","year":"2004","unstructured":"Maedler K, Storling J, Sturis J, Zuellig RA, Spinas GA, Arkhammar PO, et al. Glucose\u2013and interleukin\u20131beta induced beta\u2013cell apoptosis requires Ca2+ influx and extracellular signal\u2013regulated kinase (ERK) 1\/2 activation and is prevented by a sulfonylurea receptor 1\/inwardly rectifying K+ channel 6.2 (SUR\/Kir6.2) selective potassium channel opener in human islets. Diabetes. 2004;53(7):1706\u201313.","journal-title":"Diabetes"},{"issue":"11","key":"9623_CR10","doi-asserted-by":"publisher","first-page":"3238","DOI":"10.2337\/diabetes.54.11.3238","volume":"54","author":"N Welsh","year":"2005","unstructured":"Welsh N, Cnop M, Kharroubi I, Bugliani M, Lupi R, Marchetti P, et al. Is there a role for locally produced interleukin\u20131 in the deleterious effects of high glucose or the type 2 diabetes milieu to human pancreatic islets? Diabetes. 2005;54(11):3238\u201344.","journal-title":"Diabetes"},{"issue":"8","key":"9623_CR11","doi-asserted-by":"publisher","first-page":"2239","DOI":"10.2337\/dc12-1835","volume":"36","author":"J Sloan-Lancaster","year":"2013","unstructured":"Sloan-Lancaster J, Abu-Raddad E, Polzer J, Miller JW, Scherer JC, De Gaetano A, et al. Double-blind, randomized study evaluating the glycemic and anti-inflammatory effects of subcutaneous LY2189102, a neutralizing IL-1\u03b2 antibody, in patients with type 2 diabetes. Diabetes Care. 2013;36(8):2239\u201346.","journal-title":"Diabetes Care"},{"issue":"Suppl 1","key":"9623_CR12","first-page":"S366","volume":"54","author":"E Abu-Raddad","year":"2011","unstructured":"Abu-Raddad E, DeGaetano A, Bihorel S, Fiedler-Kelly J, Sloan-Lancaster J. Pharmacokinetic (PK) and pharmacodynamic (PD) modeling of subcutaneous (SC) LY2189102, a neutralizing IL\u20131\u03b2 antibody, in patients with type 2 diabetes mellitus. Diabetologia. 2011;54 Suppl 1:S366.","journal-title":"Diabetologia"},{"issue":"2","key":"9623_CR13","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1161\/01.CIR.0000133317.49796.0E","volume":"110","author":"SM Grundy","year":"2004","unstructured":"Grundy SM, Cleeman JI, Merz CN, Brewer Jr HB, Clark LT, Hunninghake DB, et al. Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines. Circulation. 2004;110(2):227\u201339.","journal-title":"Circulation"},{"key":"9623_CR14","unstructured":"NONMEM [computer program]. Version VI. Ellicott City, MD: ICON Development Solutions; 2006."},{"issue":"1","key":"9623_CR15","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1159\/000180580","volume":"16","author":"DW Cockcroft","year":"1976","unstructured":"Cockcroft DW, Gault MH. Prediction of creatinine clearance from serum creatinine. Nephron. 1976;16(1):31\u201341.","journal-title":"Nephron"},{"key":"9623_CR16","volume-title":"Bedside clinical pharmacokinetics: Simple techniques for individualized drug therapy","author":"CC Peck","year":"1989","unstructured":"Peck CC, Conner DP, Murphy MG. Bedside clinical pharmacokinetics: Simple techniques for individualized drug therapy. Vancouver: Applied Therapeutics, Inc; 1989."},{"issue":"2","key":"9623_CR17","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1208\/s12248-011-9255-z","volume":"13","author":"M Bergstrand","year":"2011","unstructured":"Bergstrand M, Hooker AC, Wallin JE, Karlsson MO. Prediction-corrected visual predictive checks for diagnosing nonlinear mixed-effects models. AAPS J. 2011;13(2):143\u201351. doi:10.1208\/s12248-011-9255-z.","journal-title":"AAPS J"},{"key":"9623_CR18","unstructured":"R Development Core Team (2010). R: a language and environment for statistical computing. R Foundation for Statistical Computing, Vienna, Austria. ISBN 3-900051-07-0, URL http:\/\/www.R-project.org."},{"issue":"10","key":"9623_CR19","doi-asserted-by":"publisher","first-page":"633","DOI":"10.2165\/11535960-000000000-00000","volume":"49","author":"NL Dirks","year":"2010","unstructured":"Dirks NL, Meibohm B. Population pharmacokinetics of therapeutic monoclonal antibodies. Clin Pharmacokinet. 2010;49(10):633\u201359. doi:10.2165\/11535960-000000000-00000.","journal-title":"Clin Pharmacokinet"},{"issue":"8","key":"9623_CR20","doi-asserted-by":"publisher","first-page":"493","DOI":"10.2165\/11531280-000000000-00000","volume":"49","author":"RJ Keizer","year":"2010","unstructured":"Keizer RJ, Huitema ADR, Schellens JHM, Beijnen JH. Clinical pharmacokinetics of therapeutic monoclonal antibodies. Clin Pharmacokinet. 2010;49(8):493\u2013507. doi:10.2165\/11531280-000000000-00000.","journal-title":"Clin Pharmacokinet"},{"issue":"2","key":"9623_CR21","doi-asserted-by":"publisher","first-page":"490","DOI":"10.1007\/s11095-011-0578-3","volume":"29","author":"L Kagan","year":"2012","unstructured":"Kagan L, Turner MR, Balu-Iyer SV, Mager DE. Subcutaneous absorption of monoclonal antibodies: Role of dose, site of injection, and injection volume on rituximab pharmacokinetics in rats. Pharm Res. 2012;29(2):490\u20139. doi:10.1007\/s11095-011-0578-3.","journal-title":"Pharm Res"},{"issue":"5","key":"9623_CR22","doi-asserted-by":"publisher","first-page":"548","DOI":"10.1038\/clpt.2008.170","volume":"84","author":"W Wang","year":"2008","unstructured":"Wang W, Wang EQ, Balthasar JP. Monoclonal antibody pharmacokinetics and pharmacodynamics. Clin Pharmacol Ther. 2008;84(5):548\u201358. doi:10.1038\/clpt.2008.170.","journal-title":"Clin Pharmacol Ther"},{"issue":"3","key":"9623_CR23","doi-asserted-by":"publisher","first-page":"297","DOI":"10.1002\/(SICI)1520-6017(200003)89:3<297::AID-JPS2>3.0.CO;2-P","volume":"89","author":"CJ Porter","year":"2000","unstructured":"Porter CJ, Charman SA. Lymphatic transport of proteins after subcutaneous administration. J Pharm Sci. 2000;89(3):297\u2013310.","journal-title":"J Pharm Sci"},{"issue":"1\u20132","key":"9623_CR24","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1016\/S0169-409X(01)00150-8","volume":"50","author":"MA Swartz","year":"2001","unstructured":"Swartz MA. The physiology of the lymphatic system. Adv Drug Deliv Rev. 2001;50(1\u20132):3\u201320.","journal-title":"Adv Drug Deliv Rev"},{"issue":"4","key":"9623_CR25","doi-asserted-by":"publisher","first-page":"573","DOI":"10.1046\/j.1365-2567.1996.d01-775.x","volume":"89","author":"EJ Israel","year":"1996","unstructured":"Israel EJ, Wilsker DF, Hayes KC, Schoenfeld D, Simister NE. Increased clearance of IgG in mice that lack beta 2-microglobulin: Possible protective role of FcRn. Immunology. 1996;89(4):573\u20138.","journal-title":"Immunology"},{"issue":"11","key":"9623_CR26","doi-asserted-by":"publisher","first-page":"2645","DOI":"10.1002\/jps.20178","volume":"93","author":"ED Lobo","year":"2004","unstructured":"Lobo ED, Hansen RJ, Balthasar JP. Antibody pharmacokinetics and pharmacodynamics. J Pharm Sci. 2004;93(11):2645\u201368.","journal-title":"J Pharm Sci"},{"issue":"1","key":"9623_CR27","doi-asserted-by":"publisher","first-page":"101","DOI":"10.4161\/mabs.4.1.18543","volume":"4","author":"R Deng","year":"2012","unstructured":"Deng R, Meng YG, Hoyte K, Lutman J, Lu Y, Iyer S, et al. Subcutaneous bioavailability of therapeutic antibodies as a function of FcRn binding affinity in mice. MAbs. 2012;4(1):101\u20139. doi:10.4161\/mabs.4.1.18543.","journal-title":"MAbs"},{"issue":"4","key":"9623_CR28","doi-asserted-by":"publisher","first-page":"600","DOI":"10.1124\/dmd.109.031310","volume":"38","author":"R Deng","year":"2010","unstructured":"Deng R, Loyet KM, Lien S, Iyer S, DeForge LE, Theil FP, et al. Pharmacokinetics of humanized monoclonal anti-tumor necrosis factor-\u03b1 antibody and its neonatal Fc receptor variants in mice and cynomolgus monkeys. Drug Metab Dispos. 2010;38(4):600\u20135. doi:10.1124\/dmd.109.031310.","journal-title":"Drug Metab Dispos"},{"issue":"1","key":"9623_CR29","doi-asserted-by":"publisher","first-page":"248","DOI":"10.1124\/dmd.112.048496","volume":"41","author":"L Kagan","year":"2013","unstructured":"Kagan L, Mager DE. Mechanisms of subcutaneous absorption of rituximab in rats. Drug Metab Dispos. 2013;41(1):248\u201355. doi:10.1124\/dmd.112.048496.","journal-title":"Drug Metab Dispos"},{"issue":"2","key":"9623_CR30","doi-asserted-by":"publisher","first-page":"267","DOI":"10.4161\/mabs.4.2.19364","volume":"4","author":"A Datta-Mannan","year":"2012","unstructured":"Datta-Mannan A, Witcher DR, Lu J, Wroblewski VJ. Influence of improved FcRn binding on the subcutaneous bioavailability of monoclonal antibodies in cynomolgus monkeys. MAbs. 2012;4(2):267\u201373.","journal-title":"MAbs"},{"issue":"2","key":"9623_CR31","doi-asserted-by":"publisher","first-page":"296","DOI":"10.1208\/s12248-012-9340-y","volume":"14","author":"N Chirmule","year":"2012","unstructured":"Chirmule N, Jawa V, Meibohm B. Immunogenicity to therapeutic proteins: impact on PK\/PD and efficacy. AAPS J. 2012;14(2):296\u2013302. doi:10.1208\/s12248-012-9340-y.","journal-title":"AAPS J"},{"issue":"Suppl 1","key":"9623_CR32","doi-asserted-by":"publisher","first-page":"S54","DOI":"10.1177\/0091270011413894","volume":"52","author":"B Meibohm","year":"2012","unstructured":"Meibohm B, Zhou H. Characterizing the impact of renal impairment on the clinical pharmacology of biologics. J Clin Pharmacol. 2012;52 Suppl 1:S54\u201362. doi:10.1177\/0091270011413894.","journal-title":"J Clin Pharmacol"},{"key":"9623_CR33","unstructured":"Food and Drug Administration. Guidance for industry: immunogenicity assessment for therapeutic protein products (draft guidance). http:\/\/www.fda.gov\/downloads\/Drugs\/GuidanceComplianceRegulatoryInformation\/Guidances\/UCM338856.pdf. Published Feb 2013. Accessed 22 May 2013."},{"key":"9623_CR34","first-page":"57","volume-title":"Immunology","author":"RA Goldsby","year":"2002","unstructured":"Goldsby RA, Kindt TJ, Osborne BA, Kuby J. Antigens. In: Goldsby RA, Kindt TJ, Kuby J, Osborne BA, editors. Immunology. 5th ed. New York: WH Freeman & Co Publishers; 2002. p. 57\u201375.","edition":"5"}],"container-title":["The AAPS Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1208\/s12248-014-9623-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1208\/s12248-014-9623-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1208\/s12248-014-9623-6","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1208\/s12248-014-9623-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,8]],"date-time":"2025-04-08T21:57:18Z","timestamp":1744149438000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1208\/s12248-014-9623-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,6,11]]},"references-count":34,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2014,9]]}},"alternative-id":["9623"],"URL":"https:\/\/doi.org\/10.1208\/s12248-014-9623-6","relation":{},"ISSN":["1550-7416"],"issn-type":[{"value":"1550-7416","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014,6,11]]},"assertion":[{"value":"4 March 2014","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 May 2014","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 June 2014","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}]}}